CoChat

Cost-Effectiveness of Icosapent Ethyl (IPE) for the Reduction of the Risk of Ischemic Cardiovascular Events in Canada

Open access
Lachaine, Jean, Charron, Jean-Nicolas, Gregoire, Jean C, Hegele, Robert A, Leiter, Lawrence A · 2023 · ClinicoEconomics and Outcomes Research

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

Background: Despite the use of statins, many patients with cardiovascular disease (CVD) have persistent residual risk. In a large Phase III trial (REDUCE-IT), icosapent ethyl (IPE) was shown to reduce the first occurrence of the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina. Methods: We conducted a cost-utility analysis comparing IPE to placebo in statin-treated patients with elevated triglycerides, from a publicly funded, Canadian healthcare payer perspective, using a time-dependent Markov transition model over a 20-year time horizon. We obtained efficacy and safety data from REDUCE-IT, and costs and utilities from provincial formularies and databases, manufacturer sources, and Canadian literature sources. Results: In the probabilistic base-case analysis, IPE was associated with an incremental cost of $12,523 and an estimated 0.29 more quality-adjusted life years (QALYs), corresponding to an incremental cost-effectiveness ratio (ICER) of $42,797/QALY gained. At a willingness-to-pay of $50,000 and $100,000/QALY gained, there is a probability of 70.4% and 98.8%, respectively, that IPE is a cost-effective strategy over placebo. The deterministic model yielded similar results. In the deterministic sensitivity analyses, the ICER varied between $31,823-$70,427/QALY gained. Scenario analyses revealed that extending the timeframe of the model to a lifetime horizon resulted in an ICER of $32,925/QALY gained. Conclusion: IPE represents an important new treatment for the reduction of ischemic CV events in statin-treated patients with elevated triglycerides. Based on the clinical trial evidence, we found that IPE could be a cost-effective strategy for treating these patients in Canada.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ceor.s377935

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Markov Model Structure.
Figure 1 Markov Model Structure.CC BY-NC · PubMed Central
Figure 2 Cumulative Incidence of the REDUCE-IT Individual First Primary Endpoint. From N Engl J Med, Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. 380:11–22. Copyright © 2019 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.27
Figure 2 Cumulative Incidence of the REDUCE-IT Individual First Primary Endpoint. From N Engl J Med, Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. 380:11–22. Copyright © 2019 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.27CC BY-NC · PubMed Central
Figure 3 Scatter plot of Simulation of Cost-Effectiveness Plane for IPE vs Placebo.
Figure 3 Scatter plot of Simulation of Cost-Effectiveness Plane for IPE vs Placebo.CC BY-NC · PubMed Central
Figure 4 Cost-Effectiveness Acceptability Curves for IPE vs Placebo.
Figure 4 Cost-Effectiveness Acceptability Curves for IPE vs Placebo.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 4

  1. The Conference Board of Canada. Mortality due to heart disease and stroke; 2015. Available from: https://www.conferenceboard.ca/hcp/provincial/health/heart.aspx?AspxAutoDetectCookieSupport=1. Accessed March 14, 2023.
  2. McGregor, 2003, CMAJ, 168, 433
  3. Stone Neil, 2013, Circulation, 2014, S1
  4. Canadian Agency for Drugs and Technologies in Health (CADTH). CDR Pharmacoeconomic review report for Praluent; 2016.

Cited by

See all 8

Metadata

Authors
Lachaine, J., Charron, J.-N., Gregoire, J. C., Hegele, R. A., & Leiter, L. A.
Affiliations
  • PeriPharm Inc. (Canada) (CA)
  • Robarts Research Institute (CA)
  • St. Michael's Hospital (CA)
Venue
ClinicoEconomics and Outcomes Research
Published
2023-04
Volume
Volume 15
Pages
295-308
ISSN
1178-6981 (ISSN-L)
OpenAlex
W4366588956
Cited by
7
References
43
Citations by year
2025: 3 · 2024: 1 · 2023: 2
FWCI
1.22
Type
journal article
Language
en
Open access
Locations
  • ClinicoEconomics and Outcomes Research (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Amgen
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Sanofi
  • Regeneron Pharmaceuticals
  • Ultragenyx Pharmaceutical
  • Kowa Company
  • Amryt Pharma
  • Novo Nordisk
  • Servier
  • HLS Therapeutics
  • Esperion Therapeutics
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
Keywords
icosapent ethyl, cost-effectiveness, ischemic cardiovascular events, triglyceride elevation, statin-treated patients, residual cardiovascular risk, REDUCE-IT trial, quality-adjusted life years, incremental cost-effectiveness ratio, Canada

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.